Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -421.06% is 228% below its 5-year average of -128.32%, near the low end of its 5-year range (-421.06%–-11.12%).
As of the fiscal period ended Tuesday, June 30, 2026. 51.29% below its 12-month average of -278.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -421.06%.
RETURN ON EQUITY (ROE)
-421.06%
RETURN ON EQUITY (ROE) AVG TTM
-278.31%
RETURN ON EQUITY (ROE) AVG 3Y
-152.86%
RETURN ON EQUITY (ROE) AVG 5Y
-128.32%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-51.29%
CURRENT VS 3Y AVG
-175.46%
CURRENT VS 5Y AVG
-228.15%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-902.28%
vs the sector median at left
LeonaBio, Inc.
Market Cap
$22.20M
Return on Equity (ROE)
-421.06%
TTM Avg
-278.31%
3Y Avg
-152.86%
5Y Avg
-128.32%
Market Cap
$22.13M
Return on Equity (ROE)
-260.37%
TTM Avg
-164.08%
3Y Avg
-188.26%
5Y Avg
-64.22%
Market Cap
$22.00M
Return on Equity (ROE)
-40.40%
TTM Avg
-55.95%
3Y Avg
-53.10%
5Y Avg
-83.38%
Market Cap
$22.92M
Return on Equity (ROE)
-487.90%
TTM Avg
-205.19%
3Y Avg
-102.69%
5Y Avg
-68.50%
Market Cap
$23.26M
Return on Equity (ROE)
-0.80%
TTM Avg
-5.04%
3Y Avg
68.38%
5Y Avg
100.94%
Market Cap
$23.88M
Return on Equity (ROE)
N/A
TTM Avg
-294.82%
3Y Avg
229.70%
5Y Avg
122.55%
Market Cap
$20.29M
Return on Equity (ROE)
-351.86%
TTM Avg
-122.41%
3Y Avg
-86.06%
5Y Avg
-64.41%
Market Cap
$20.16M
Return on Equity (ROE)
-313.46%
TTM Avg
-251.20%
3Y Avg
-178.74%
5Y Avg
-144.62%
Market Cap
$24.59M
Return on Equity (ROE)
-140.55%
TTM Avg
-62.02%
3Y Avg
-44.98%
5Y Avg
-43.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | $22.20M | -421.06% | -278.31% | -152.86% | -128.32% |
| Modular Medical, Inc. (MODD)vs › | $22.13M | -260.37% | -164.08% | -188.26% | -64.22% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | -40.40% | -55.95% | -53.10% | -83.38% |
| Rein Therapeutics Inc. (RNTX)vs › | $22.92M | -487.90% | -205.19% | -102.69% | -68.50% |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | -0.80% | -5.04% | 68.38% | 100.94% |
| Kyntra Bio, Inc. (KYNB)vs › | $23.88M | N/A | -294.82% | 229.70% | 122.55% |
| NextCure, Inc. (NXTC)vs › | $20.29M | -351.86% | -122.41% | -86.06% | -64.41% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.16M | -313.46% | -251.20% | -178.74% | -144.62% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | -140.55% | -62.02% | -44.98% | -43.41% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.91M | -76.82% | -235.52% | -335.24% | -272.42% |
ROE
-421.1%
ROA
-248.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -421.06% |
| 2026-03-31 | -262.49% |
| 2025-12-31 | -380.03% |
| 2025-09-30 | -140.83% |
| 2025-06-30 | -187.12% |
| 2025-03-31 | -213.62% |
| 2024-12-31 | -216.19% |
| 2024-09-30 | -189.68% |
| 2024-06-30 | -136.14% |
| 2024-03-31 | -108.85% |
| 2023-12-31 | -90.39% |
| 2023-09-30 | -77.87% |
| 2023-06-30 | -58.24% |
| 2023-03-31 | -48.54% |
| 2022-12-31 | -40.67% |
| 2022-09-30 | -31.21% |
| 2022-06-30 | -27.56% |
| 2022-03-31 | -22.18% |
| 2021-12-31 | -17.08% |
| 2021-09-30 | -13.75% |
| 2021-06-30 | -11.12% |
| 2021-03-31 | -7.44% |
| 2020-12-31 | -7.28% |
| 2020-09-30 | -5.10% |
| 2020-06-30 | -7.88% |
